Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
SUBSCRIBE FOR FREE
Facebook
Twitter
LinkedIn
Cancerworld Magazine
Cancerworld Magazine
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine > News > Study opens way for using antifibrotic drugs to prevent metastasis
  • News

Study opens way for using antifibrotic drugs to prevent metastasis

  • 10 October 2024
  • Janet Fricker
Study opens way for using antifibrotic drugs to prevent metastasis
Total
0
Shares
0
0
0
0
0

Adding a drug currently used against idiopathic pulmonary fibrosis to chemotherapy in the neoadjuvant setting increased event-free survival in patients with early HER2-negative breast cancer. The study, published in Clinical Cancer Research, 16 September, found that high levels of fibrosis in the microenvironment predicted poor outcomes, and that those poorer outcomes could be corrected by the anti-fibrotic drug nintedanib.

“This strategy defines a pathway toward more personalised and lower-cost treatment paradigms for breast cancer and represents the first successful clinical application targeting tumor fibrosis in oncology,” write the authors, led by Ghassan Mouneimne, from the University of Arizona Cancer Center, in Tucson, Arizona.

Tumour stiffening is a feature of the progression of breast cancer, producing a varied microenvironment ‘landscape’, which ranges from normal elasticity to fibrotic-like tissue stiffness. The stiffness is caused by the extracellular matrix (the network of proteins and other molecules surrounding cells) having increased collagen deposition, which increases the tissue rigidity/stiffness. “Whether a tissue is fibrotic or not is largely determined by the amount of collagen fibres secreted by fibroblasts and whether bundled and cross-linked together,” Mouneimne tells Cancerworld.

When cancer cells are surrounded by stiff matrix, the physical resistance triggers ‘mechanotransduction’, defined as a rapid conversion of mechanical stimuli into biochemical signals. Mechanotransduction has been shown to promote the first steps of metastasis by increasing cytoskeletal dynamics, cell migration, and invasion in situ. A study published in Nature Nanotechnology in 2012 showed that extracellular matrix stiffening was implicated in tumour progression.

A fundamental aspect of the current study is the mechanical conditioning (MeCo) score that Mouneimne and Adam Watson devised to provide a quantitative measure of how cancer cells become influenced by stiffness in their extracellular matrix. In a study published in Cell Reports in 2021, they developed tissue culture in vitro models exposing breast cancer cell lines to hydrogels with both high and low levels of stiffness. Next, they performed RNA sequencing gene expression analysis to see which genes were ’dialed up and down’ in the cancer cells in the soft and stiff matrices. Differential expression analysis revealed that 930 genes were upregulated and 1,795 downregulated by >2 fold increases in stiffness. The gene sets were then further refined to develop the MeCo score, which was then validated using long-term survival data from four studies involving more than 2500 patients. “The MeCo score is not a biomarker of fibrosis, but rather a biomarker of the response to fibrosis, a measure of the problematic potential of the actual cancer cells that will exert a devastating effect when they migrate to a different setting during metastasis,” explains Mouneimne.

For the current analysis, Mouneimne calculated MeCo scores for patients who had previously taken part in an earlier Phase 2 trial exploring whether the drug nintedanib had anti-angiogenic properties in HER2 negative breast cancer.

For the study, originally undertaken by Miguel Quintela Fandino from the Spanish National Cancer Research Centre (first published in British Journal of Cancer in 2014), 130 patients with early HER2-negative breast cancer were randomised 1:1 to the experimental arm, receiving nintedanib plus paclitaxel in the neoadjuvant setting prior to surgery, or the control arm, receiving just paclitaxel.

Nintedanib was of interest in the treatment of fibrosis, because it is an agent known to exert a powerful anti-fibrotic activity through blockade of the fibroblast growth factor receptor (FGFR) family. Notably, it was the first disease-modifying therapy approved for idiopathic lung fibrosis.

For the current analysis, the team generated RNA sequence data from patients in the earlier 2014 study, which enabled them to calculate baseline MeCo scores. These scores could then be compared with data on survival outcomes after the team collected long-term follow-up data from all the study sites. Patients were divided into high MeCo scores (prespecified as above the median) and low MeCo scores (below the median). For the new analysis, this gave rise to four separate patient groups: those with high MeCo scores treated with nintedanib, those with high scores who were not treated with nintedanib, those with low scores who were treated with nintedanib, and those with low scores who were not treated with nintedanib.

Results at a median follow-up of 9.67 years showed median event-free survival was not statistically different overall between the experimental arm who received nintedanib and the control arm who did not receive nintedanib (P=0.37).

However, when patients were split according to their MeCo score, the results suggest a positive therapeutic effect for nintedanib, specific to patients with fibrotic high MeCo tumours. In the control arm (who did not receive nintedanib), patients with high MeCo scores had statistically higher relapse rates than those with low scores (HR=0.21; P=0.0075). In the experimental arm, however, that higher risk was corrected by nintedanib, resulting in no statistical difference between patients with high versus low MeCo scores (HR=0.37; P=0.16).

Furthermore, nintedanib demonstrated pharmacodynamic engagement, reducing the MeCo score by 25% during the run-in phase of the trial (P<0.01).

“When patients are split by their MeCo score, the results suggest a positive therapeutic effect of nintedanib that is specific for fibrotic High MeCo tumors. In the absence of anti-fibrotic treatment, patients with elevated scores suffer from a very aggressive disease course,” conclude the authors.

Introducing nintedanib into the neoadjuvant setting, they believe, has the potential to increase overall survival in some patients with high levels of fibrosis. “By offering a specific therapy targeting the biological feature identified by the MeCo score, nintedanib could provide a rational therapeutic option for high-risk groups,” write the authors. Importantly, the approach would be cost-effective, adds Mouneimne, since nintedanib is now off-patent.

The team are currently looking to develop cancer-specific MeCo scores for prostate and colorectal cancers, and are in the early stages of planning a prospective multicentre trial using the MeCo score test to inform nintedanib use in patients with luminal ER-positive breast cancer. Pavani Chalasani, from the George Washington Cancer Center, Washington DC, will be the principal investigator.  “Ultimately, we hope that patients will be able to get access to their MeCo scores to decide whether they would benefit from anti-fibrotic therapy in the neoadjuvant setting before surgery,” says Mouneimne.

Reducing fibrosis in the microenvironment, he adds, is likely to deliver additional benefits, including allowing drugs to more easily access the cancer cells and influencing the immune system.

The opening illustration shows a rendering of nintedanib bound to its target in the RET protein tyrosine kinase domain (PDB ID: 6NEC). Artistic rendering made by Behnoush Hajian.

Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Related Topics
  • antifibrotic
  • HER2-negative breast cancer
  • mechanical conditioning
  • MeCo score
  • nintedanib
  • repurposing
  • tumour extracellular matrix
  • tumour fibrosis
Janet Fricker

Janet Fricker is a medical writer specialising in oncology and cardiology. After researching articles for Cancerworld she runs, swims, and eats porridge.

Previous Article
  • News

Nobel Prize for medicine awarded for discovery of microRNAs, which play key role in cancer development

  • 10 October 2024
  • Janet Fricker
View Post
Next Article
  • Voices

Voices from Gaza: caught between conflict and cancer

  • 10 October 2024
  • Marwa Koçak
View Post
You May Also Like
View Post
  • News

Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study

  • Janet Fricker
  • 8 May 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in April: Oncology’s Top Moments

  • Yeva Margaryan
  • 7 May 2025
View Post
  • News

CancerWorld #102 (April 2025)

  • Yeva Margaryan
  • 22 April 2025
View Post
  • News
  • Senza categoria

What Caught Our Eye in March: Oncology’s Top Moments

  • Janet Fricker
  • 8 April 2025
View Post
  • News

Ovarian cancer: mechanism conferring resistance to immunotherapy revealed

  • Janet Fricker
  • 21 March 2025
View Post
  • News

Muscular strength and cardiorespiratory fitness improve survival in cancer patients

  • Janet Fricker
  • 20 March 2025
View Post
  • News

CancerWorld #101 (February 2025): The Must-Read Oncology Issue Returns to Print with Exclusive Interviews and Breakthroughs

  • Yeva Margaryan
  • 18 March 2025
View Post
  • News

Low-dose aspirin reduces colorectal cancer recurrence in patients with PI3K alterations

  • Janet Fricker
  • 6 March 2025
search
CancerWorld #101 Download CancerWorld #101 Download CancerWorld #101 Download or search in Cancerworld archive
Newsletter

Subscribe free to
Cancerworld!

We'll keep you informed of the latest features and news with a fortnightly email

Subscribe now
Latest News
  • Personalised neoantigen vaccine for kidney cancer shows promise in phase 1 study
    • 8 May 2025
  • What Caught Our Eye in April: Oncology’s Top Moments
    • 7 May 2025
  • CancerWorld #102 (April 2025)
    • 22 April 2025
  • What Caught Our Eye in March: Oncology’s Top Moments
    • 8 April 2025
  • Ovarian cancer: mechanism conferring resistance to immunotherapy revealed
    • 21 March 2025
Article
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • Istanbul, Ankara take action on HPV vaccination, as government delays promised national programme
    • 1 April 2025
  • Could this dual approach be the frontier that finally gets immunotherapy to work for MSS colorectal cancer?
    • 31 March 2025
Social

Would you follow us ?

Contents
  • Miriam Merad and the 2025 Sjöberg Prize: A Celebration of Innovation in Cancer Immunotherapy
    • 6 May 2025
  • “I really care about people.” – Philip Kantoff, A Life in Science and Medicine
    • 5 May 2025
  • What If the World’s Leading Prostate Cancer Epidemiologist Opened a Restaurant? A Conversation with Lorelei Mucci- A Harvard Scientist, A Mother, A Leader
    • 23 April 2025
MENU
  • About the Magazine
    • About us
    • Editorial Team
    • Events
    • Archive
    • Contacts
  • Articles
    • Policy
    • Practice Points
    • Delivery of Care
    • Biology basic
    • Medicine
    • Featured
  • Contents
    • News
    • Editorials
    • Interviews to the Expert
    • In the Hot Seat
    • Profiles
    • Obituaries
    • Voices
  • ESCO Corner
Cancerworld Magazine
  • About us
  • Articles
  • Media Corner
  • Privacy Policy
  • Cookie Policy

Cancerworld is published by OncoDaily (P53 Inc.) | Mailing Address: 867 Boylston st, 5th floor, Ste 1094 Boston, MA 02116, United States | [email protected]

Archivio Cancerworld

Input your search keywords and press Enter.